[go: up one dir, main page]

NO2007017I2 - 3-[2-[4-(6-fluor-1,2-benzoksazol-3-yl)-1-piperidinyl]etyl]-6,7,8,9-tetrahydro-9-hydroksy-2-metyl-4H-pyridol]1,2-a]pyrimidin-4-on(palperidone) - Google Patents

3-[2-[4-(6-fluor-1,2-benzoksazol-3-yl)-1-piperidinyl]etyl]-6,7,8,9-tetrahydro-9-hydroksy-2-metyl-4H-pyridol]1,2-a]pyrimidin-4-on(palperidone)

Info

Publication number
NO2007017I2
NO2007017I2 NO2007017C NO2007017C NO2007017I2 NO 2007017 I2 NO2007017 I2 NO 2007017I2 NO 2007017 C NO2007017 C NO 2007017C NO 2007017 C NO2007017 C NO 2007017C NO 2007017 I2 NO2007017 I2 NO 2007017I2
Authority
NO
Norway
Prior art keywords
piperidinyl
hydroxy
palperidone
pyridol
benzoxazol
Prior art date
Application number
NO2007017C
Other languages
English (en)
Other versions
NO2007017I1 (no
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO2007017I1 publication Critical patent/NO2007017I1/no
Publication of NO2007017I2 publication Critical patent/NO2007017I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO2007017C 1988-11-07 2007-12-21 3-[2-[4-(6-fluor-1,2-benzoksazol-3-yl)-1-piperidinyl]etyl]-6,7,8,9-tetrahydro-9-hydroksy-2-metyl-4H-pyridol]1,2-a]pyrimidin-4-on(palperidone) NO2007017I2 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26785788A 1988-11-07 1988-11-07

Publications (2)

Publication Number Publication Date
NO2007017I1 NO2007017I1 (no) 2008-01-14
NO2007017I2 true NO2007017I2 (no) 2010-01-25

Family

ID=23020416

Family Applications (2)

Application Number Title Priority Date Filing Date
NO894411A NO173015C (no) 1988-11-07 1989-11-06 Analogifremgangsmaate til fremstilling av pyrido(1,2-a)pyrimidin-3-piperidinyl-1,2-benzisoksazoler
NO2007017C NO2007017I2 (no) 1988-11-07 2007-12-21 3-[2-[4-(6-fluor-1,2-benzoksazol-3-yl)-1-piperidinyl]etyl]-6,7,8,9-tetrahydro-9-hydroksy-2-metyl-4H-pyridol]1,2-a]pyrimidin-4-on(palperidone)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO894411A NO173015C (no) 1988-11-07 1989-11-06 Analogifremgangsmaate til fremstilling av pyrido(1,2-a)pyrimidin-3-piperidinyl-1,2-benzisoksazoler

Country Status (21)

Country Link
EP (1) EP0368388B1 (no)
JP (1) JP2758045B2 (no)
KR (1) KR0146053B1 (no)
AT (1) ATE122349T1 (no)
AU (1) AU614437B2 (no)
CA (1) CA2000786C (no)
CL (1) CL43432B (no)
CY (2) CY1926A (no)
DE (2) DE122007000081I2 (no)
DK (1) DK169923B1 (no)
ES (1) ES2075036T3 (no)
FI (1) FI92201C (no)
HK (1) HK131696A (no)
IE (1) IE66370B1 (no)
IL (1) IL92208A0 (no)
LU (1) LU91362I2 (no)
NL (1) NL300298I2 (no)
NO (2) NO173015C (no)
NZ (1) NZ231062A (no)
PT (1) PT92206B (no)
ZA (1) ZA898436B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
US5378714A (en) * 1991-11-27 1995-01-03 Novo Nordisk A/S Antipsychotic piperidine derivatives
NZ245260A (en) * 1991-11-27 1995-06-27 Novo Nordisk As Piperidine derivatives, preparation and pharmaceutical compositions thereof
ES2050069B1 (es) * 1992-07-10 1994-12-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
DK60793D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
SK282231B6 (sk) * 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
EP0730594B1 (en) * 1993-11-23 1999-09-08 Janssen Pharmaceutica N.V. 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US6326362B1 (en) 1998-05-18 2001-12-04 Sepracor Inc. (-)-phosphonorisperidone and (-)-sulforisperidone compositions and methods
WO1999059590A1 (en) * 1998-05-18 1999-11-25 Sepracor Inc. (+)-hydroxyrisperidone compositions and methods
AU5489299A (en) 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
ES2197801B1 (es) 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
EP1560814A1 (en) 2002-11-13 2005-08-10 Synthon B.V. Process for making risperidone and intermediates therefor
CN101014601B (zh) * 2004-09-09 2011-09-14 詹森药业有限公司 制备9-羟基-3-(2-羟基乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮及其晶体
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP2133352A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
EP2133351A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
EP1940834A2 (en) 2006-08-14 2008-07-09 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone)
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
EP1924583A2 (en) * 2006-08-23 2008-05-28 Teva Pharmaceutical Industries Ltd. Process for the synthesis of cmhtp and intermediates thereof
WO2008087557A2 (en) * 2007-01-08 2008-07-24 Actavis Group Ptc Ehf An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
BRPI0809837A2 (pt) * 2007-04-19 2014-11-11 Youxin Li "composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
WO2009010988A1 (en) * 2007-07-19 2009-01-22 Natco Pharma Limited An improved, industrially viable process for the preparation of high purity paliperidone
WO2009015828A1 (en) * 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
WO2009045489A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of cmhtp, a paliperidone intermediate
KR20100091959A (ko) * 2007-10-09 2010-08-19 시플라 리미티드 팔리페리돈 및 그의 약학적으로 허용가능한 염의 제조방법 및 상기 제조방법에 사용되는 중간체
US7977480B2 (en) 2007-12-10 2011-07-12 Synthon Bv Synthesis of paliperidone
US20100311969A1 (en) * 2008-02-05 2010-12-09 Watson Pharma Private Limited Process For Preparation of Paliperidone
EP2285804A4 (en) * 2008-04-21 2011-09-14 Glenmark Generics Ltd METHOD FOR MANUFACTURING PALIPERIDONE INTERMEDIATES
EP2303877B1 (en) 2008-05-29 2017-02-15 Inke, S.A. Process to prepare paliperidone and intermediates thereof
US8481729B2 (en) 2008-06-16 2013-07-09 Msn Laboratories Limited Processes for the preparation of paliperidone
WO2010003703A2 (en) * 2008-07-11 2010-01-14 Synthon B.V. Paliperidone ketone
EP2321311B1 (en) * 2008-07-11 2012-09-19 Synthon B.V. Synthesis of paliperidone
SI22856A (sl) * 2008-07-31 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Proces za pripravo paliperidona
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
EP2199293A1 (en) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. One-step process for preparing paliperidone and its oxalate salt
EP2202234A1 (en) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification of paliperidone
SI2275423T1 (sl) 2009-07-13 2012-06-29 Krka D.D., Novo Mesto Postopek za sintezo paliperidona
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (en) * 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
CN103313712B (zh) 2010-11-15 2016-10-26 艾吉因生物股份有限公司 用于治疗认知障碍的哒嗪衍生物、组合物和方法
CN102153552B (zh) * 2011-03-01 2012-08-22 吉林大学 两种帕潘立酮药物共晶及其制备方法
CN102206210B (zh) * 2011-04-01 2014-07-02 常州市第四制药厂有限公司 一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10329301B2 (en) 2013-12-20 2019-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN113264939A (zh) 2015-06-19 2021-08-17 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2019162746A1 (en) * 2018-02-21 2019-08-29 Zenvision Pharma Llp Novel derivatives of paliperidone and process for the preparation thereof
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN116003404B (zh) * 2022-12-14 2024-10-01 杭州同舟生物技术有限公司 一种利培酮人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
FI92201C (fi) 1994-10-10
FI92201B (fi) 1994-06-30
DK551989D0 (da) 1989-11-06
JP2758045B2 (ja) 1998-05-25
JPH02191276A (ja) 1990-07-27
ATE122349T1 (de) 1995-05-15
CY2007025I2 (el) 2009-11-04
CL43432B (es) 2005-06-03
ZA898436B (en) 1991-07-31
DK169923B1 (da) 1995-04-03
CY1926A (en) 1989-10-30
KR0146053B1 (ko) 1998-08-17
EP0368388A2 (en) 1990-05-16
ES2075036T3 (es) 1995-10-01
DE122007000081I2 (de) 2010-01-28
AU4443689A (en) 1990-05-10
KR910009700A (ko) 1991-06-28
NO894411D0 (no) 1989-11-06
DK551989A (da) 1990-05-08
DE122007000081I1 (de) 2008-02-28
PT92206A (pt) 1990-05-31
CY2007025I1 (el) 2009-11-04
FI895261A0 (fi) 1989-11-06
NL300298I2 (nl) 2008-03-03
HK131696A (en) 1996-07-26
LU91362I2 (fr) 2007-11-12
NO173015C (no) 1993-10-13
IL92208A0 (en) 1990-07-26
CA2000786C (en) 1999-01-26
PT92206B (pt) 1995-07-06
NO173015B (no) 1993-07-05
IE893564L (en) 1990-05-07
EP0368388B1 (en) 1995-05-10
NO894411L (no) 1990-05-08
NZ231062A (en) 1991-09-25
DE68922577T2 (de) 1995-09-28
IE66370B1 (en) 1995-12-27
CA2000786A1 (en) 1990-05-07
EP0368388A3 (en) 1991-07-17
NL300298I1 (nl) 2007-12-03
DE68922577D1 (de) 1995-06-14
NO2007017I1 (no) 2008-01-14
AU614437B2 (en) 1991-08-29

Similar Documents

Publication Publication Date Title
NO2007017I2 (no) 3-[2-[4-(6-fluor-1,2-benzoksazol-3-yl)-1-piperidinyl]etyl]-6,7,8,9-tetrahydro-9-hydroksy-2-metyl-4H-pyridol]1,2-a]pyrimidin-4-on(palperidone)
FI900085A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(pyrimidin- ja kondensoitu pyrimidin-4-oni)etyyli-piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
EP0206415A3 (en) (4-piperidinylmethyl and -hetero)purines
EP0151824A3 (en) N-(4-piperidinyl) bicyclic condesed 2-imidazolamine derivatives
NO176051C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperazinylbenzazol-derivater
JPS6425776A (en) Piperidine derivative
NO176608C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater